The short version of hGH fragment fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-28. Anything still debated is marked as such rather than presented as settled.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
According to US Chamber of Commerce 70% of all illicit drug users are employed. Some industries have high rates of employee drug use such as construction (12.8%), repair (11.1%), and hospitality (7.9-16.3%).
During the 2010s, Valve began focusing on supporting their established multiplayer games with regular content updates. In the late 2010s, Valve began investing in virtual reality and started to develop games and other software that make use of the technology, such as Half-Life: Alyx. Valve is considered one of the most important and influential companies in the games industry. The reception of their games, along with the creation of Steam, has prompted some publications to list Valve as one of the top game developers of all time and the most powerful company in PC gaming. Newell received a BAFTA Fellowship award in 2013 for recognizing the impact Valve had left on the gaming industry in producing several successful game franchises.
Bacteria also use contact-dependent signaling, notably to limit their growth. Signaling molecules used by multicellular organisms are often called pheromones. They can have such purposes as alerting against danger, indicating food supply, or assisting in reproduction.
=== The pre-war situation in Bosnia and Herzegovina === With the fall of communism and the start of the break-up of Yugoslavia, the old communist doctrine of tolerance began to lose its strength, creating an opportunity for nationalist elements in the society to spread their influence. On the first multi-party elections that took place in November 1990 in Bosnia and Herzegovina, the three largest ethnic parties in the country won: the Bosniak Party of Democratic Action, the Serbian Democratic Party and the Croatian Democratic Union of Bosnia and Herzegovina. After the elections, they formed a coalition government. Parties shared power along the ethnic lines so that the President of the Presidency of the Socialist Republic of Bosnia and Herzegovina was a Bosniak, president of the Parliament was a Bosnian Serb and the prime minister a Bosnian Croat.
Sources: en.wikipedia.org
He added, "It's an honor to be with you, it's an honor to be your friend", while saying he hoped the relationship would be "better than ever before". The two leaders then had talks behind closed doors following the opening remarks. The talks lasted two hours in total, double the duration originally scheduled. The two leaders exchanged views on the Iran war, the Russo-Ukrainian war, and the Korean Peninsula. The White House stated that the two sides had "discussed ways to enhance economic cooperation", including by US companies' access to the Chinese economy and Chinese investment in US industries. The statement also said they discussed the importance of ending the flow of fentanyl precursors into the US. Regarding the Iran war, the White House said "both countries agreed that Iran can never have a nuclear weapon" and that "the two sides agreed that the Strait of Hormuz must remain open to support the free flow of energy", while adding Xi had expressed opposition to the militarization of the Strait of Hormuz and efforts to charge a toll for its use and expressed interest in China buying oil from the US. The Financial Times later reported that, Xi had condemned Japanese prime minister Sanae Takaichi for Japan's "remilitarisation", with Xi reportedly becoming "vocal and agitated when discussing Japan". Adding that this was the most intense part of Trump's visit, the Financial Times reported Trump had responded by saying Japan had to take a more assertive defense stance due to rising threats from North Korea.
Extrion became the dominant manufacturer of ion implanters. By the late 1970s, ion implantation was standard practice throughout the semiconductor industry, enabling the MOS integrated circuits that would dominate late twentieth-century electronics.
Medical cannabis, or medical marijuana, refers to the use of herbal cannabis or its preparations to treat disease or improve symptoms. There is no single agreed-upon definition (e.g., cannabinoids derived from cannabis and synthetic cannabinoid analogs are also used). The rigorous scientific study of cannabis as a medicine has been hampered by production restrictions and by the fact that it is classified as an illegal drug by many governments. Evidence supports only a few approved uses of cannabinoids and most medical claims, such as efficacy for insomnia or acute pain, lack sufficient evidence; benefits, risks, and harm-reduction strategies should be evaluated before clinical recommendations of cannabis or cannabinoids. There is some evidence suggesting cannabis can be used to reduce nausea and vomiting during chemotherapy, to improve appetite in people with HIV/AIDS, or to treat chronic pain and muscle spasms. Evidence for its use for other medical applications is insufficient for drawing conclusions about safety or efficacy. There is evidence supporting the use of cannabis or its derivatives in the treatment of chemotherapy-induced nausea and vomiting, neuropathic pain, and multiple sclerosis. Lower levels of evidence support its use for AIDS wasting syndrome, epilepsy, rheumatoid arthritis, and glaucoma. The medical use of cannabis is legal only in a limited number of territories, including Belgium, Australia, the Netherlands, New Zealand, Spain, and many U.S. states.
Sources: en.wikipedia.org
During World War II and the Cold War, the Hanford Site produced plutonium for U.S. nuclear weapons for more than 50 years. The plutonium for the first plutonium bomb, Fat Man, also came from there. Hanford is considered the most radioactively contaminated site in the Western Hemisphere. A total of 110,000 tons of nuclear fuel was produced there. In 1948, a radioactive cloud leaked from the plant. The amount of 131I alone was 5500 curies. Most of the reactors at Hanford were shut down in the 1960s, but no disposal or decontamination was done. After preliminary work, the world's largest decontamination operation began at Hanford in 2001 to safely dispose of the radioactive and toxic waste. In 2006, some 11,000 workers were still cleaning up contaminated buildings and soil to reduce radiation levels at the site to acceptable levels. This work is expected to continue until 2052. It is estimated that more than four million liters of radioactive liquid have leaked from storage tanks. It was only after the two superpowers agreed on a Partial Test Ban Treaty in 1963, which allowed only underground nuclear weapons testing, that the level of radioactivity in food began to decline. Shields Warren (1896-1980), one of the authors of a report on the effects of the atomic bombs dropped on Japan, was criticized for downplaying the effects of residual radiation in Hiroshima and Nagasaki, but later warned of the dangers of fallout. Fallout refers to the spread of radioactivity in the context of a given meteorological situation. A model experiment was conducted in 2008.
The peptidoglycan layer within the bacterial cell wall is a crystal lattice structure formed from linear chains of two alternating amino sugars, namely N-acetylglucosamine (GlcNAc or NAG) and N-acetylmuramic acid (MurNAc or NAM). The alternating sugars are connected by a β-(1,4)-glycosidic bond. Each MurNAc is attached to a short (4- to 5-residue) amino acid chain, containing L-alanine, D-glutamic acid, meso-diaminopimelic acid, and D-alanine in the case of Escherichia coli (a gram-negative bacterium); or L-alanine, D-glutamine, L-lysine, and D-alanine with a 5-glycine interbridge between tetrapeptides in the case of Staphylococcus aureus (a gram-positive bacterium). Peptidoglycan is one of the most important sources of D-amino acids in nature. By enclosing the inner membrane, the peptidoglycan layer protects the cell from lysis caused by the turgor pressure of the cell. When the cell wall grows, it retains its shape throughout its life, so a rod shape will remain a rod shape, and a spherical shape will remain a spherical shape for life. This happens because the freshly added septal material of synthesis transforms into a hemispherical wall for the offspring cells. Cross-linking between amino acids in different linear amino sugar chains occurs with the help of the enzyme DD-transpeptidase and results in a 3-dimensional structure that is strong and rigid. The specific amino acid sequence and molecular structure vary with the bacterial species. The different peptidoglycan types of bacterial cell walls and their taxonomic implications have been described.
Autofluorescence is the natural fluorescence of biological structures (autofluorophores) such as mitochondria and lysosomes, in contrast to fluorescence originating from artificially added fluorescent markers (fluorophores). The most commonly observed autofluorescencing molecules are NADPH and flavins; the extracellular matrix can also contribute to autofluorescence because of the intrinsic properties of collagen and elastin. Generally, proteins containing an increased amount of the amino acids tryptophan, tyrosine, and phenylalanine show some degree of autofluorescence. Autofluorescence also occurs in non-biological materials found in many papers and textiles. Autofluorescence from U.S. paper money has been demonstrated as a means for discerning counterfeit currency from authentic currency.
There are several pressure-lowering medication groups that could be used in lowering the IOP, usually eyedrops. The choice of medication usually depends on the dose, duration, and side effects of each medication. However, in general, prostaglandin analogues are the first-line treatment for glaucoma. Prostaglandin analogues, such as latanoprost, bimatoprost, and travoprost, reduce the IOP by increasing the aqueous fluid outflow through the draining angle. It is usually prescribed once daily at night. The systemic side effects of this class are minimal. However, they can cause local side effects, including redness of the conjunctiva, a change in the iris color, and eyelash elongation. Several other classes of medications could be used as a second-line in case of treatment failure or presence of contraindications to prostaglandin analogues. These include:
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.